Prognosis in women with interval breast cancer: Population based observational cohort study

BMJ (Online)

Volumn 345, Issue 7885, 2012, Pages

  Kalager, Mette ^a,b,c   Tamimi, Rulla M ^a,d   Bretthauer, Michael ^b,e   Adami, Hans Olov ^a,f  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c TELEMARK HOSPITAL   (Norway)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGE; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GROWTH RATE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NORWAY; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84870523099     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e7536     Document Type: Article

References (34)

1. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol BiomarkersPrev 2005;14:1108-12. (Pubitemid 40656455)
2. Gilliand FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000;92:743-9. (Pubitemid 30365535)
3. Sihto H, Lundin J, Lehtimäki T. Molecular subtypes of breast cancer detected in mammography screening and outside of screening. Clin Cancer Res 2008;14:4103-10.
4. Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO. Improved breast cancer survival following introduction of an organized mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res 2009;1:R44.
5. Zackrisson S, Janzon L, Manjer J, Andersson I. Improved survival rate for women with interval breast cancer-results from the breast cancer screening programme in Malmö, Sweden 1976-1999. J Med Screen 2007;14:138-43. (Pubitemid 47511123)
6. Wang H, Bjurstam N, Bjørndal H, Braaten A, Eriksen L, Skaane P, et al. Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int J Cancer 2001;94:594-8.
7. Holmberg LH, Adami HO, Tabar L, Bergström R. Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 1986;2:27-30. (Pubitemid 16063767)
8. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ. Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 1995;31:1830-5.
9. Schröen AA, Wobbes T, van der Sluis RF. Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 1996;63:141-4. (Pubitemid 26404552)
10. Collins S, Woodman CBJ, Threlfall A, Prior P. Survival rates from interval cancers in NHS breast screening programme. BMJ 1998;316:832-3. (Pubitemid 28112432)
11. Bordás P, Jonsson H, Nyström L, Lenner P. Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast 2007;16:47-54. (Pubitemid 46172856)
12. Lawrence G, O'Sullivan E, Kearins O, Tappenden N, Martin K, Wallis M. Screening histories of invasive breast cancers diagnosed 1989-2006 in the West Midlands, UK: variation with time and impact on 10-year survival. J Med Screen 2009;16:186-92.
13. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010;363:1203-10.
14. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 2009;45:1218-31.
15. Tingulstad S, Haldorsen T, Norstein J, Hagen B, Skjeldestad FE. Completeness and accuracy of registration of ovarian cancer in the cancer registry of Norway. Int J Cancer 2002;98:907-11. (Pubitemid 34286689)
16. Wang H, Kåresen R, Hervik A, Thoresen S. Mammography screening in Norway: results from the first screening round in four counties and cost effectiveness of a modeled nationwide screening. Cancer Causes Control 2001;12:39-45. (Pubitemid 32140393)
17. Perry N, Broeders M, de Wolf C. European guidelines for quality assurance in breast cancer screening and diagnosis. 2nd edn. Office for official publications of the European Communities, 1996.
18. Erzaas A. Quality assurance manual of the norwegian breast cancer screening program [Norwegian]. The Cancer Registry of Norway; 2003. www.kreftregisteret.no.
19. Cowan WK, Angus B, Gray JC, Lunt LG, Al-Tamimi SR. A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 2000;53:140-6.
20. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancers and survival in a randomised breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992;24:11-6. (Pubitemid 23012688)
21. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC cancer staging manual, 7th edn. Springer-Verlag, 2010.
22. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992;22:207-19.
23. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8. (Pubitemid 15062653)
24. Andersson I, Aspgren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmö mammographic trial. BMJ 1988;29:943-8.
25. Vitak B, Stål O, Månson JC, Thomas BA, Arnesson LG, Ekelund L, et al. Interval cancers and cancers in non-attenders in the Östergötland mammographic screening programme. Duration between screening and diagnosis, s-phase fraction and distant recurrence. Eur J Cancer 1997;33:1453-60. (Pubitemid 27404905)
26. Rayson D, Payne JI, Abdolell M, Barnes PJ, MacIntosh RF, Foley T, et al. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study. Clin Breast Cancer 2011;11:27-32.
27. DeGroote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM. Interval breast cancer: a more aggressive subset of breast neoplasias. Surgery 1983;94:543-7. (Pubitemid 13012174)
28. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-55. (Pubitemid 12018584)
29. Hofvind S, Skaane P, Vitak B, Wang H, Thoresen S, Eriksen L, et al. Influence of review design on percentages of missed interval breast cancers: a retrospect study of interval cancers in a population-based screening program. Radiology 2005;237:437-43. (Pubitemid 41507877)
30. Hofvind S, Geller B, Skaane P. Mammographic features and histopathological findings of interval breast cancers. Acta Radiol 2008;49:975-81.
31. Vitak B. Interval cancers in the Ostergötland Mammographic Screening Program: radiological analysis. Eur Radiol 1998;8:639-46. (Pubitemid 128546289)
32. Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martínez J, et al. Phenotypic characterizations and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 2010;21:1155-64.
33. Vitak B, Olsen KE, Månson JC, Arnesson LG, Stål O. Tumor characteristics and survival in patients with invasive interval breast cancer classified according to mammographic findings at the latest screening: a comparison of true interval and missed interval cancers. Eur Radiol 1999;9:460-9.
34. Porter GJR, Evans AJ, Burrell AJ, Lee AHS, Ellis IO, Chakrabarti J. Interval breast cancers: prognostic features and survival by subtype and time since last screen. J Med Screen 2006;13:115-22. (Pubitemid 44452722)